Trials / Completed
CompletedNCT05202145
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
A Three-Part Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2050 and Cyclosporine, Tacrolimus, and Mycophenolate Mofetil in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN2050 | Oral tablet. |
| DRUG | Cyclosporine | Oral capsule. |
| DRUG | Tacrolimus | Oral capsule. |
| DRUG | MMF | Oral tablet. |
Timeline
- Start date
- 2022-01-11
- Primary completion
- 2022-03-21
- Completion
- 2022-03-21
- First posted
- 2022-01-21
- Last updated
- 2023-04-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05202145. Inclusion in this directory is not an endorsement.